Dyspepsia Clinical Trial
Official title:
Evaluation of Gastric Emptying Time, Gastric Electrical Activity and Gastrointestinal Peptides to Identify Dyspeptic Patients With Epigastric Pain Syndrome From Those With Postprandial Distress Syndrome According to the Rome III Proposed Subdivision of Functional Dyspepsia
Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms from the
gastroduodenal region in the absence of any organic, systemic or metabolic disease that is
likely to explain the symptoms. FD can be further subdivided into two diagnostic categories:
postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS).
Disorders of gastric electric activity and abnormal gastric emptying are probably actively
involved in the FD onset. Different noninvasive procedures may be applied in order to
evaluate the gastric motor functions such as 13C breath testing and cutaneous
electrogastrography. Besides, different gastrointestinal peptides (i.e. CCK, peptide YY,
Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II) are
involved in the control of gastroduodenal motility.
Aims of the present study are: 1) to evaluate the GI peptide circulating concentrations, the
gastric electrical activity and gastric emptying time by applying noninvasive procedures in
patients suffering from functional dyspepsia and 2) to test whether a significant difference
exists between the two diagnostic categories of meal-induced dyspeptic symptoms
Functional dyspepsia is one of the most relevant functional gastrointestinal disorders
(FGIDs) among general population. Rome III criteria defined functional dyspepsia as the
presence of symptoms from the gastroduodenal region (early satiation, postprandial fullness,
epigastric pain or burning) in the absence of any organic, systemic or metabolic disease
that is likely to explain the symptoms. Etiological causes are still unclear, and the
pathophysiological mechanisms still largely unknown. Besides, Helicobacter pylori infection
is often present in these patients and contributes to complicate the clinical presentation.
One of the main problem in the management of these patients is the lack of reliable
biohumoral markers. Thus, functional disorders are usually diagnosed on the bases of
symptomatic patterns. The Rome consensus has proposed to further subdivide FD into two
diagnostic categories of meal-induced dyspeptic symptoms: postprandial distress syndrome
(PDS), characterized by postprandial fullness and early satiation, and epigastric pain
syndrome (EPS), characterized by epigastric pain and burning.
Central processing of visceral stimuli, and its role in the pathogenesis of functional
dyspepsia, as well as low-grade inflammation in the duodenum are important emerging topics
in pathophysiology research. In this framework, disorders of gastric electric activity and
abnormal gastric emptying are probably actively involved in the onset of symptomatology.
Different noninvasive procedures may be applied in order to evaluate the gastric motor
functions. Among them, gastric emptying time evaluation by 13C breath testing and cutaneous
electrogastrography have raised attention for their reliability and potentiality. Another
important pathophysiological concern of FD is represented by the possible alterations in
circulating concentrations of different gastrointestinal peptides at various degree involved
in the control of gastroduodenal motility [namely Cholecystokinin (CCK), peptide YY,
Neurotensin, Somatostatin, Leptin, Ghrelin, Motilin, Gastrin, Pepsinogen I and II]. In
previous studies significant lower levels of motilin was found in dyspeptic patients with
altered antroduodenal motility was found. CCK mediates satiety by acting on the CCK
receptors distributed widely throughout the central nervous system as well as effects on the
vagus nerve. Other experimental data suggest that somatostatin and neurotensin may affect
muscle contractility and delay the intestinal transit.
On these bases aims of the study will be: 1) to evaluate the GI peptide circulating
concentrations, the gastric electrical activity and gastric emptying time by applying
noninvasive procedures in patients suffering from functional dyspepsia and 2) to test
whether a significant difference exists between the two diagnostic categories of
meal-induced dyspeptic symptoms
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Withdrawn |
NCT02863822 -
Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.
|
N/A | |
Recruiting |
NCT00978159 -
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
|
Phase 4 | |
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Completed |
NCT00148603 -
Montelukast in the Treatment of Duodenal Eosinophilia
|
N/A | |
Terminated |
NCT00220844 -
Tricyclic Antidepressants (TCAs) on Gastric Emptying
|
N/A | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00110968 -
Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia
|
Phase 3 | |
Completed |
NCT00232102 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00164996 -
Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia
|
Phase 3 | |
Completed |
NCT00232037 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05718960 -
Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
|
N/A | |
Completed |
NCT05750641 -
The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
|
||
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Completed |
NCT04697641 -
Helicobacter Pylori Eradication in Functional Dyspepsia
|
N/A | |
Completed |
NCT03252743 -
ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.
|
N/A | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|